Author | Jeffrey E. Lancet, MD | OncLive

Author | Jeffrey E. Lancet, MD


Dr. Lancet on CPX-351 in Elderly Patients With AML

July 28, 2016


Jeffrey E. Lancet, MD, medical oncologist, Moffitt Cancer Center, discusses results of a randomized phase III study comparing the efficacy of CPX-351 (Vyxeos) versus daunorubicin (7+3) plus cytarabine in older patients with newly diagnosed, high-risk acute myeloid leukemia (AML).